Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric naloxegol pharmacokinetics and safety study in opioid-treated patients
NL-OMON44584Phase 1Withdrawn
- Sponsor
- Kyowa Kirin
- Start
- Mar 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naloxegol in opioid-induced constipation (OIC), sponsored by Kyowa Kirin. Primary endpoints: Single-dose pharmacokinetics and population pharmacokinetics of naloxegol and Safety and tolerability of naloxegol. Planned start Mar 2014; status: withdrawn.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NL-OMON44584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44584.